Andrew Choi, MD
Cardiovascular Disease · Washington, DCNPI 1487813234
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,912 of the $31,741 with a category attached, or 65.9%. Cleerly, Inc. accounts for 64.7% of it on its own, with 22 other manufacturers making up the rest. Among cardiovascular disease clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $330.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$21K
- Butterfly Network, Inc.$2K
- Amgen$2K
- Abbott$2K
- Siemens Medical Solutions USA, Inc.$2K
- Edwards Lifesciences$1K
- plus $1K from 17 others
Across 17 payments — averaging $7188.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$85K
- Cleerly, Inc.$37K
Across 3 payments — averaging $3332.99 each. An ownership or investment interest held by the physician or an immediate family member.
- Cleerly, Inc.$10K
What the payments were for
- Consulting fees$20,91266%
- Speaking & faculty fees$1,6505%
- Travel & lodging$3,01910%
- Food & beverage$3,72912%
- Education$320%
- Other$2,3998%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 11 | $20,533 |
| Butterfly Network, Inc. | 1 | $2,399 |
| Amgen | 2 | $2,385 |
| Abbott | 18 | $1,924 |
| Siemens Medical Solutions USA, Inc. | 1 | $1,650 |
| Edwards Lifesciences | 22 | $1,384 |
| Canon Medical Systems USA, Inc. | 2 | $535 |
| Medtronic(2 entities) | 13 | $344 |
| Bracco Diagnostics Inc. | 5 | $144 |
| Angiodynamics, Inc. | 3 | $73 |
| Novo Nordisk | 2 | $66 |
| Boston Scientific | 2 | $44 |
| Cook Medical LLC | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Novartis | 2 | $33 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| GE HealthCare | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Pfizer | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Butterfly iQ$2,399
- TRICLIP$856
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$561
- TOSHIBA SCANNER$535
- SAPIEN 3 Ultra RESILIA$391
- Cleerly Ischemia$332
- Cleerly Labs$332
- NAVITOR$287
- MitraClip$124
- CardioMEMS HF System$114
- Micra$101
How this compares
$31,741 in reported general payments places this provider in the 90th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $11,561 |
| Repatha SureclickEvolocumab | 16 | $10,676 |
| XareltoRivaroxaban | 13 | $9,817 |
| JardianceEmpagliflozin | 13 | $9,040 |
| Ezetimibe | 47 | $1,580 |
| Rosuvastatin Calcium | 49 | $671 |
| Atorvastatin Calcium | 86 | $649 |
| Metoprolol Succinate | 31 | $377 |
| Carvedilol | 37 | $289 |
| Amlodipine Besylate | 39 | $229 |
| Losartan Potassium | 24 | $213 |
| Chlorthalidone | 16 | $187 |
| Pravastatin Sodium | 12 | $144 |
| Furosemide | 14 | $66 |
| Pantoprazole Sodium | 19 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $11,56111 claims |
| Johnson & JohnsonXarelto | $18 | $9,81713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 105 cardiovascular disease providers in District of Columbia.
Other cardiovascular disease in Washington
- Hayder HashimWashington$824K
- Joshua YamamotoWashington$376K
- Mardi Gomberg-MaitlandWashington$320K
- Jaffar KhanWashington$318K
- Isaac Opoku-AsareWashington$146K
- Judith HsiaWashington$65K
- Ana BaracWashington$34K
- Jonathan PlehnWashington$32K
- Felton AndersonWashington$23K
- Jose VargasWashington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.